Paraneoplastic sensitive neuropathy is one of the most common presentations among a group of cancer-related disorders known as Paraneoplastic Neurological Syndromes (PNS). PNS likely have an autoimmune etiology since they have been associated with the presence of antibodies against neuronal antigens expressed by tumor cells (such as anti-Hu, anti-Ri and anti-Yo). The tumors most frequently associated with PSN and onconeural antibodies are lung cancer, lymphomas and gynaecological tumors; however, they have also been described in other tumors. We report, for the first time, a case of neuroendocrine tumor of duodenum and PNS associated with anti-Hu antibodies. Moreover, we analyze and discuss the clinical implications that PNS and anti-Hu could have in patients with tumors.
Paraneoplastic neurological syndromes (PSN) are neurological disorders of unknown cause often associated with cancer. In many tumors neurological manifestations are due to central or peripheral nervous system metastases but, in a minority group, they are independent from secondary tumor development. Therefore, PNS definition has changed in the last twenty years because their different pathogenetic mechanisms are not always identifiable. The discovery that many PNS could be associated with antibodies against neuronal antigens expressed by tumors allowed the recognition of an autoimmune etiology for these syndromes. The most well-known antibodies are anti-Yo, anti-Ri and anti-Hu (1). However, PNS may occur without onconeural antibodies, which can be found without a neurological syndrome; therefore, their presence should not be the only condition for defining a neurological syndrome as paraneoplastic. PSN are frequently associated with small cell lung cancer (SCLC), lymphomas and gynaecological tumors (2-3), although they have also been described in other types of cancer. To date, PNS and duodenum neuroendocrine tumors have never been reported.
We present a case of a patient with a neuroendocrine tumor of duodenum and PNS with associated anti-Hu antibodies.
Case report
The patient, a 63-year-old man, is currently under treatment at our Institution. In June 2008, after abdominal pain, a total body CT scan was carried out which highlighted a voluminous, solid, expansive neo-formation, inseparable from pancreas uncinato process, completely surrounding the third duodenum portion and inseparable from colon hepatic flexure.
He also presented abdominal lymph node metastasis, with no involvement of liver and lungs ( Fig. I A) .
In August 2008 he underwent a non-radical surgical cephalic duodenopancreatectomy with a histological diagnosis of poorly differentiated, non-secreting, neuroendocrine tumor of duodenum. After surgery ( Fig. I B) the patient started chemotherapeutic treatment with carboplatin, AUC 5, day I, and 100 mg/m2 Etoposide, days 1-3 every 21 days. He obtained a partial response documented after 3 and 6 cycles ( Fig. I C and D) , then started a treatment with the somatostatin analog octreotide obtaining an additional tumor reduction ( Fig. 2 A) .
While receiving octreotide, the patient reported paresthesias, numbness and progressive reduction of tactile sensibility, all limited to the upper limbs, apparently unrelated to the specific tumor treatments, and unresponsive to common therapy with steroids and pregabalin 300 mg/die. The patient did not present neurological symptoms of the lower limbs.
After nine months of octreotide therapy he experienced a disease progression ( Fig. 2 B) associated with a worsening ofneuropathic syndrome. In October 2009, he suspended the octreotide and re-started chemotherapy with the same drugs, carboplatin and etoposide, and the schedule used previously, obtaining a new partial response (80% target lesion reduction) after 3 cycles of treatment ( Fig. 2 C) , accompanied by a continuous and irreversible neuropathy. Electroneurography showed a global reduction/absence of sensitive responses in upper limbs and no alterations in the lower limbs; no abnormal electromyographic findings were observed in the upper and lower limbs. Neurophysiopathological exams indicated a diagnosis of ganglionopathy of unknown etiology. The search for antibodies against neuronal antigens was positive for anti-Hu antibodies and negative for anti-Yo and anti-Ri antibodies.
The neurological examination revealed a symmetric reduction of tactile and vibration sensitivity without motor deficit in upper arts, with paresthesias and pallestesias.
Based on the electroneurographic and clinical findings, the demonstration of anti-Hu antibodies, the development of the neurological syndrome and the related symptoms, in spite of the reported tumor response, we diagnosed a paraneoplastic sensitive neuropathy.
DISCUSSION
PNS diagnosis is based on clinical features and the finding of specific antibodies. The presence of anti-neural antibodies strongly indicates that a neurological syndrome is paraneoplastic, however, their absence does not exclude the presence of a tumor. Anti-Yo, anti-Ri and anti-Hu antibodies are the most frequently described, associated with paraneoplastic neuropathy.
Anti-Ri antibodies are directed against 55 and 80 KDa neural nuclear proteins and have been discovered in patients with opsoclonus-myoclonus and breast cancer (4).
Anti-Yo antibodies recognize 34 and 62 Kd proteins localized in Purkinje cell cytoplasm and in neoplastic cells ofpatients affected by paraneoplastic cerebellar degeneration and breast and ovarian cancer (5) . Anti-Hu antibodies are directed against a 37-40 KDa nuclear protein localized in neurons, and have been found in patients with subacute sensory neuropathy and encephalomyelitis, and with SCLC (6). Other types of antibodies have been only rarely identified.
The pathogenetic significance of these antibodies is not yet clear, but, most likely, results from an immune reaction against antigens present in both the tumor and nervous system. PNS and neuronal antibodies are strongly associated with some tumors, especially with SCLC, breast cancer and gynecological tumors (5) . Rarely and occasionally an association also with other tumors has been reported. In particular, paraneoplastic cerebellar degeneration and anti-Yo antibodies were found in adenocarcinoma of the gastroesophageal junction, gastric adenocarcinoma and esophageal adenocarcinoma (7) . Some cases of PNS and neuronal antibodies have been described in neuroendocrine tumors. They are generally carcinoid tumors originating from lung, but isolated cases of PSN and carcinoid of the cecum, stomach and rectum are also described (8) . A PNS in neuroendocrine tumors of duodenum has never been reported previously.
Anti-Hu antibodies are often expressed in lung neuroendocrine tumors (9) and are associated to sensory neuronopathy, especially peripheral neuropathy. Subacute sensory neuropathy is the most frequent presentation and it likely derives from an immune disruption of neuronal cell bodies in dorsal root ganglia. The course of the neuropathy could be acute (5%), subacute (55%) or progressive (40%), as in this presented case. Clinically the neuropathy could be sensory (70%), sensorimotor (25%) or motor (5%), and symmetrical (65%), asymmetrical (25%) or multifocal (10%). Pain is the predominant symptom (10). Anti-Hu antibodies proved to be important, not only for diagnosis but also for their correlation with clinical outcome.
Preclinical and clinical studies support a correlation between the presence of autoantibodies and tumor response to treatment. Two preclinical studies demonstrated that HuD cause tumor growth inhibition and cytotoxic responses in mouse models (11) .
In a multicenter prospective study on patients with SCLC, the presence of anti-Hu antibodies at the time of diagnosis, was a strong and independent predictor of complete response to treatment and was associated with longer survival (12) .
Another retrospective study highlighted the relationship between paraneoplastic encephalomyelitis (PEM) and better prognosis in patients with SCLC (13) .
Finally, one study demonstrated that in patients with modest plasma levels of anti-Hu antibodies tumor progression is more favorable than in patients with SCLC without anti-Hu antibodies (14) . These data are in agreement with the clinical features of the case we describe here. Our patient, in fact, obtained a partial response after chemotherapy and octretide, with a long time to tumor progression and a second partial response to the same original chemotherapic regimen after the first disease progression.
PNS treatment is based on plasmapheresis, intravenous immunoglobulins and immunosuppressors (such as cyclophosphamide, methotrexate and steroids) (15) . However, there are no well-documented responses to any immunotherapy, alone or in combination. Moreover, a spontaneous regression of neurological symptoms has been described in some patients. The only effective treatment for PNS seems to be chemotherapy, as demonstrated by Guibert and colleagues in a retrospective analysis of SCLC and anti-Hu-associated encephalomyelitis (PEM). In that study they compared tumor response and PEM in patients treated with chemotherapy with or without immunotherapy. Complete response of tumor was the only predictor ofPEM stabilization. On the other hand, immunotherapy did not affect tumor response and PEM (14) .
In conclusion, we report the first case of a patient with a paraneoplastic sensitive neuropathy associated with anti-Hu antibodies and neuroendocrine tumor of duodenum. This patient was unresponsive to immunotherapy while he obtained a first partial response to chemotherapy and octreotide, with a long interval before tumor progression, and a second response to the same regimen after progressive disease. PNS could be the first manifestation of a potentially curable tumor. More studies are necessary to understand the clinical significance of the finding of onconeural antibodies for the diagnosis and prognosis of these tumors.
